Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 11/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.59 |
| ▸ | MEF2D | Q14814 | 2/20 | 0.53 |
| ▸ | EP300 | Q09472 | 1/20 | 0.53 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.45 |
| ▸ | KLK7 | P49862 | 2/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5280493 | 1.00 | HDAC1 (0.60) | HDAC1HDAC4HDAC6MEF2DEP300 | |
| SCHEMBL8260908 | 0.91 | HDAC1 (0.73) | HDAC1HDAC4HDAC6MEF2DEP300 | |
| SCHEMBL5287405 | 0.90 | HDAC1 (0.62) | HDAC1HDAC4HDAC6MEF2DEP300 | |
| SCHEMBL5326785 | 0.88 | HDAC1 (0.71) | HDAC1HDAC4HDAC6MEF2DEP300 | |
| SCHEMBL5326792 | 0.88 | HDAC1 (0.71) | HDAC1HDAC4HDAC6MEF2DEP300 | |
| SCHEMBL8259289 | 0.86 | HDAC1 (0.68) | HDAC1HDAC4HDAC6MEF2DEP300 | |
| SCHEMBL8260503 | 0.84 | HDAC1 (0.64) | HDAC1HDAC4HDAC6MEF2DEP300 | |
| SCHEMBL5278245 | 0.83 | HDAC1 (0.55) | HDAC1HDAC4HDAC6MEF2DEP300 | |
| SCHEMBL8252976 | 0.83 | HDAC4 (0.58) | HDAC1HDAC4HDAC6MEF2DEP300 | |
| SCHEMBL5281071 | 0.83 | ANPEP (0.53) | HDAC1HDAC4HDAC6MEF2DEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | claimed |
| EP-1863804-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2007-12-12 | — | — | EP | disclosed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | disclosed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | HDAC1 1/4885HDAC4 7/4885HDAC6 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.